Calcium channel blocker nasal spray treats paroxysmal supraventricular tachycardia

Key Result

Etripamil, a calcium channel blocker nasal spray, has been approved for the treatment of periodic paroxysmal supraventricular tachycardia.

Key Points

• To evaluate the efficacy of etripamil nasal spray in treating paroxysmal supraventricular tachycardia (PSVT).
• Evaluated etripamil as a nasal spray for PSVT treatment.
• Provided training for patients on symptom management and spray administration.
• Etripamil is approved for PSVT treatment.
• Patients can effectively manage PSVT symptoms immediately with this nasal spray.